Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients
NCT00985426
Completed
The purpose of the study is to demonstrate the safety and immunogenicity of a new investigational hepatitis B virus vaccine, HEPLISAV-B, in patients 18 to 75 years of age who have progressive loss of kidney function.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/28/2021
Locations: Clinical Research Associates of Tidewater, Norfolk, Virginia
Conditions: Chronic Kidney Disease
Register for Updates
Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
NCT02045836
Completed
The purpose of this study is to assess the immunogenicity, reactogenicity and safety of the GSK Biologicals HZ/su candidate vaccine when its first dose is co-administered with Pneumovax 23™ vaccine in adults aged 50 years or older.The impact of HZ/su vaccine on Pneumovax 23™ vaccine immune response will also be evaluated.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/19/2021
Locations: GSK Investigational Site, Golden, Colorado +8 locations
Conditions: Herpes Zoster, Herpes Zoster Vaccine
Register for Updates
Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age
NCT02075515
Completed
The purpose of this study is to demonstrate lot-to-lot consistency in terms of immunogenicity, and evaluate safety of the Herpes Zoster subunit (HZ/su) vaccine. The study is designed as a randomized, double-blind study with three parallel groups.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/19/2021
Locations: GSK Investigational Site, Mesa, Arizona +7 locations
Conditions: Herpes Zoster, Herpes Zoster Vaccine
Register for Updates
Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
NCT01976520
Unknown
This Phase I trial studies the safety and efficacy of vaccine therapy in treating patients with previously untreated chronic lymphocytic leukemia. Liposome-based vaccines containing an extract of a person's cancer cells and the immunostimulant interleukin-2 may help the body to build an effective immune response to kill cancer cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/07/2021
Locations: Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois
Conditions: Chronic Lymphocytic Leukemia (CLL)
Register for Updates
Pneumococcal Conjugate Vaccine in Aging Renal Transplant
NCT03802994
Terminated
The goal of the research proposed in the current application is to first define how much antibody aging renal transplant and dialysis recipients make after they are vaccinated with the pneumonia vaccine and how this compares to similar aged persons with good renal function and healthy young adults. The investigators will study differences in the kind of B cells and markers on the B cells that are known to be important in the response to the pneumonia vaccine in aging renal transplant and aging d... Read More
Gender:
ALL
Ages:
Between 35 years and 75 years
Trial Updated:
04/06/2021
Locations: Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina +1 locations
Conditions: Renal Transplantation, Aging
Register for Updates
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
NCT00118274
Completed
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cyclophosphamide may also stimulate the immune system in different ways and stop tumor cells from growing. Giving vaccine therapy together with cyclophosphamide after surgery may cause a stronger immune response... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
03/25/2021
Locations: Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania +2 locations
Conditions: Melanoma (Skin)
Register for Updates
FLUAD® vs. Fluzone® High-Dose Study
NCT03183908
Completed
The overall aim of the study is to compare safety and immunogenicity of inactivated influenza vaccine (IIV), adjuvanted (FLUAD®) versus High-Dose inactivated influenza (Fluzone® High-Dose) vaccine in persons ≥65 years (20% aged ≥80 years). A prospective, randomized, blinded clinical trial that will be conducted during the 2017/2018 and 2018/2019 influenza seasons. During each season, approximately 220 older adults will be enrolled at Duke University Medical Center and 140 older adults at Boston... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
03/04/2021
Locations: Centers for Disease Control and Prevention, Atlanta, Georgia +3 locations
Conditions: Pain, Quality of Life, Injection Site Reaction, Side Effect of Drug, Adverse Drug Event
Register for Updates
Safety of LAIV4 in Children With Asthma
NCT03600428
Completed
This is a prospective randomized, open label clinical trial in approximately 300 children aged 5-11 years with a physician diagnosis of persistent asthma. Participants will be randomized 1:1 to receive either a single intranasal dose of licensed quadrivalent LAIV (LAIV4) or an intramuscular injection of quadrivalent IIV4 (IIV4).
Gender:
ALL
Ages:
Between 5 years and 11 years
Trial Updated:
02/25/2021
Locations: Duke University Medical Center, Durham, North Carolina +2 locations
Conditions: Asthma in Children, Vaccine Adverse Reaction, Vaccine Reaction, Asthma, Wheezing, Influenza
Register for Updates
A Single-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Hantaan Puumala Virus DNA Vaccine
NCT02776761
Completed
This is a single-center, randomized, single-blinded study of the Hantaan virus HTNV DNA vaccine alone, Puumala virus PUUV DNA vaccine alone, and mixed Hantaan/Puumala HTNV/PUUV DNA vaccines delivered intramuscularly IM by the needle-free PharmaJet Stratus DSJI device.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
02/10/2021
Locations: WRAIR Clinical Trials Center, Silver Spring, Maryland
Conditions: Hantaan Virus
Register for Updates
Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria
NCT00870987
Completed
The purpose of this study is to test the safety and effectiveness of a new malaria vaccine, the DNA-Ad vaccine. The study is specifically looking at a vaccine regimen against Plasmodium falciparum, the most deadly form of malaria.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
02/10/2021
Locations: Clinical Trials Center, WRAIR, Silver Spring, Maryland
Conditions: Malaria
Register for Updates
Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever
NCT02116205
Completed
The purpose of this study is to compare the immune responses of two different doses (1.0 mg and 2.0 mg) and two different dosing schedules (two doses or three doses) of a mixed Hantaan virus (HTNV) and Puumala virus (PUUV) DNA vaccine in healthy participants. To maintain a blind, participants in the two-dose group will receive one dose of normal saline placebo. All of the groups will also receive a booster dose 6 months after first vaccination. The results will help to determine which dose and v... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
02/10/2021
Locations: Walter Reed Army Institute of Research Clinical Trials Center, Silver Spring, Maryland
Conditions: Hemorrhagic Fever With Renal Syndrome
Register for Updates
Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis
NCT02309515
Terminated
This randomized phase II trial studies how well lenalidomide improves immune response to pneumococcal 13-valent conjugate vaccine in patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or monoclonal B cell lymphocytosis. Biological therapies, such as lenalidomide, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Lenalidomide may also improve the effectiveness of pneumococcal 13-val... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2021
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +2 locations
Conditions: Monoclonal B-Cell Lymphocytosis, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma
Register for Updates